Registration trials regarding pegylated interferon treatment of Hepatitis C have created great expectations for improved results.
However, there is little information on actual outcomes in everyday hospital practice.
Dr Guido Piai and colleagues from Italy defined the effectiveness of this treatment in a hospital setting.
The research team retrospectively analyzed 74 naïve patients with Hepatitis C treated with 12 kD-pegylated-interferon-α-2-b/ribavirin.
|Sustained viral response ranged from 48% to 61% in trials|
|Digestive Diseases & Sciences|
The team compared these patients with 54 patients treated with interferon-α-2-b/ribavirin, or standard interferon, and with results of 3 main registration trials.
Overall sustained viral response rates were 46% in the standard interferon group and 54% in pegylated-interferon-α-2-b/ribavirin group.
The team noted that overall sustained viral response ranged from 48% to 61% in similar arms of the registration trials considered.
More of the researcher's patients presented comorbidity and high-grade fibrosis.
The researchers reported that their dosages at outset of pegylated-interferon-α-2-b/ribavirin were lower than optimal.
Dr Piai's team comments, “In our hospital setting, the effectiveness of pegylated-interferon-α-2-b/ribavirin therapy appeared similar to that reported in large registration trials.”/p>